The accumulation of multiple genetic abnormalities in individual tumor cells in human breast cancers: Clinical prognostic implications

Cancer Journal from Scientific American

Volumn 2, Issue 2, 1996, Pages 106-113

  Shackney, Stanley E ^a,b   Pollice, Agnese A ^a   Smith, Charles A ^a   Alston, Lucille ^b   Singh, Sarita G ^a   Janocko, Laura E ^a   Brown, Kathryn A ^a   Petruolo, Susan ^a   Groft, David W ^a   Yakulis, Robert ^b   Hartsock, Robert J ^b  

^a ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Flow cytometry; Genetic evolution; Oncogenes; Ploidy

Indexed keywords

DNA;

ARTICLE; BREAST TUMOR; CHROMOSOME ABERRATION; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; MORTALITY; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; PROGNOSIS;

EID: 3042972715     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
2. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. New Engl J Med 1988;319:525-532.
3. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. New Engl J Med 1992;326:737-740.
4. Janocko LE, Groft DW, Brown KA et al. Assessment of sequential oncogene amplification in human breast cancer. Cytometry 1995;21:18-22.
5. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res 1990;50:6130-6138.
6. Theodorescu D, Cornil I, Sheehan C, Man S, Kerbel RS. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer 1991;47:118-123.
7. Price JE, Bell C, Frost P. The use of a genotypic marker to demonstrate clonal dominance during the growth and metastasis of a human breast carcinoma in nude mice. Int J Cancer 1990;45:968-971.
8. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993;14:482-485.
9. Varley JM, Swallow JE, Brammar WJ, Wittaker JL, Walker RA. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987;1:423-430
10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-181.
11. Guerin M, Barrois M, Terrier M-J, Spielmann M, Riou G. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 1988;3:21-31.
12. Wright C, Angus B, Nicholoson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-2090.
13. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
14. Borg A, Tandon AK, Sigurdsson H et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.
15. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
16. Paterson MC, Dietrich KD, Danyluk J et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;51:556-567.
17. McCann AH, Dervan PA, O'Regan M et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-3303.
18. Allred DC, Clark GM, Tandon AK et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
19. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-1048.
20. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056.
21. Pollice AA, McCoy JP Jr, Shackney SE et al. Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. Cytometry 1992;13:432-444.
22. Shackney SE, Burholt DR, Pollice AA, Smith CA, Pugh RP, Hartsock RJ. Discrepancies between flow cytometric and cytogenetic studies in the detection of aneuploidy in human solid tumors. Cytometry 1990;11:94-104.
23. Ritch PS, Shackney SE, Schuette WH, Talbot TL, Smith CA. A practical graphical method for estimating the fraction of cells in S in DNA histograms from clinical tumor samples containing aneuploid cell populations. Cytometry 1983;4:66-74.
24. Rohloff AC, Sakach JM, Shackney SE. Analytical approaches relating genetic evolutionary pathways to prognostic factors. Cytometry 1995;21:23-29.
25. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
26. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 1994;330:1260-1266.
27. Gusterson BA, Machin LG, Gullick WJ et al. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 1988;58:453-457.
28. Van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New Engl J Med 1988;319:1239-1245.
29. Ro J, El-Naggar A, Ro JY et al. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 1989;49:6941-6944.
30. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128.
31. Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer 1990;65:1794-1800.
32. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-948.
33. Gullick WJ, Love SB, Wright C et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-438.
34. Winstanley J, Cooke T, Murray GD et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991;63:447-450.
35. Press MF, Pike MC, Chazin VR et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
36. Koscielny S, Tubiana M, Le MG et al. Breast cancer: relationship between the size of the tumour and the probability of the metastatic dissemination. Br J Cancer 1984;49:709-715.